PSA Member Advocates for Controlled Substances Database
Michael Ashburn, MD, MPH, a PSA member, provided information to the Pennsylvania House Human Services Committee on June 16 regarding the possible creation of a controlled substances database. Legislation to create a new controlled substances database (CSDB) in Pennsylvania, House Bill 1651, was introduced in the state House of Representatives in early June.
Supporters say that an effective CSDB would help lower non-medical use of controlled substances and improve access to care.
The Pennsylvania Medical Society (PAMED) began educating legislators and their staffs on the need for a better CSDB last fall. Dr. Ashburn’s presentation on June 16 continued those outreach efforts.
Along with being a PSA board member, Dr. Ashburn is Professor of Anesthesiology and Critical Care Medicine at the Hospital of the University of Pennsylvania, Director at Pain Medicine and Palliative Care, chair of the Pennsylvania Pain Coalition (PPC), and a member of the PAMED Pain Management Work Group.
Pennsylvania’s current prescription drug database can only be accessed by the Office of the Attorney General and only collects information on Schedule II drugs.
HB 1651, which was referred to the House Human Services Committee on June 8, would require timely reporting of all Schedule II-V medications dispensed within the state and allow physicians and their authorized agents electronic access to the database to obtain data regarding their patients.
Back to list